Clinical Research

 
Stock Quotes for Clinical Research top ^
  • Industry: Business Services
  • Sector: Industrials
Sign-up for vmcs investment picks

 
News Articles for Clinical Research top ^
Walgreens (NYSE:WAG) (Nasdaq:WAG) today announced it is expanding its Healthcare Clinic retail locations with entry into the Dallas-Fort Worth market.
Sign-up for Walgreens Announces Healthcare Clinic Expansion into Dallas-Fort Worth Market investment picks
Retail clinics continue to play a growing and important role in health care delivery in the U.S., and a new research study from Walgreens (NYSE: WAG) (Nasdaq: WAG) shows patients are relying more on nurse practitioners at retail clinics to provide chronic and preventive health services.
Sign-up for More Patients Turning to Retail Clinics for Chronic Care and Preventive Services, New Walgreens Study Shows investment picks
2014/7/10
CLEVELAND , July 10, 2014 /PRNewswire/ -- Parker Hannifin Corporation (NYSE: PH) , the global leader in motion and control technologies, announced it is developing more than 100 potential medical advancements with Cleveland Clinic, the noted nonprofit academic medical center that integrates clinical care with research and education.
Sign-up for Parker Collaborates with Cleveland Clinic to Develop Advanced Medical Technologies investment picks
2014/7/16
Agilent Technologies Inc. (NYSE:A) today introduced the SureSelect Clinical Research Exome .
Sign-up for TRADE NEWS: Agilent Technologies Introduces New Exome Optimized for Clinical Research Sequencing investment picks
2014/7/17
Cigna (NYSE: CI) and Harbin Clinic , the largest privately owned multispecialty medical clinic in Georgia, have launched a collaborative care initiative to improve patient access to health care, enhance care coordination , and achieve the goal of improved health , affordability and patient experience .
Sign-up for Harbin Clinic and Cigna Start Collaborative Care Program to Improve Health and Lower Costs investment picks
ROCHESTER, Minn.
Sign-up for Mayo Clinic and IBM Task Watson to Improve Clinical Trial Research investment picks
2014/7/9
Cigna (NYSE: CI) and The Austin Diagnostic Clinic have launched a collaborative care initiative to improve patient access to health care, enhance care coordination , and achieve the goal of improved health , affordability and patient experience .
Sign-up for The Austin Diagnostic Clinic and Cigna Start Collaborative Care Program to Improve Health and Lower Costs investment picks
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs.
Sign-up for Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs investment picks
Bristol-Myers Squibb (NYSE:BMY) today announced a collaboration with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency.
Sign-up for Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute investment picks
2014/6/18
All of the more than 250 Walgreens pharmacies and 35 Healthcare Clinic at select Walgreens throughout Ohio are now offering MMR (measles, mumps, rubella) vaccinations daily with no appointment necessary, in response to this week’s executive order from Gov.
Sign-up for All Walgreens and Healthcare Clinic Locations Across Ohio Now Offering MMR Vaccinations in Response to Executive Order investment picks
BOSTON , July 1, 2014 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL) ("PAREXEL" or the "Company"), a global clinical research organization , announced today that the Company has acquired all of the outstanding equity securities of ATLAS Medical Services ("ATLAS"), a provider of clinical research services in Turkey , the Middle East , and North Africa .
Sign-up for PAREXEL International Announces Acquisition Of ATLAS Medical Services, A Provider Of Clinical Research Services In Turkey investment picks
Data from Urinary Cell-free DNA Presented at Next Generation Dx Summit WASHINGTON , Aug.
Sign-up for Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics investment picks
Exact Sciences Corp.
Sign-up for Exact Sciences Announces Mayo Clinic as First Healthcare System to Offer Cologuard® investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas.
Sign-up for Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology investment picks
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and ICON plc , (NASDAQ:ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials.
Sign-up for Medidata and ICON Join Forces to Bring New Productivity to Capturing Patient Voice in Clinical Trials investment picks
Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx ® Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.
Sign-up for Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention investment picks
2014/6/24
Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO , June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx ® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.
Sign-up for Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention investment picks
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT.
Sign-up for XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Integration  |  Next: Clinical Research Programs